

Table S1. MRI brain volume characteristics of MS patients treated with teriflunomide or dimethyl fumarate over the follow-up, who were examined only on the 3T scanner.

	0–12 Months			12–24 Months			0–24 Months		
	TFM (n = 39)	DMF (n = 45)	<i>p</i> -Value	TFM (n = 31)	DMF (n = 37)	<i>p</i> -Value	TFM (n = 31)	DMF (n = 37)	<i>p</i> -Value
PBVC	-0.98 (1.4)	-1.1 (1.5)	0.876	-1.04 (1.1)	-1.30 (1.7)	0.530	-1.50 (1.6)	-2.1 (1.6)	0.188
PGMVC	-0.34 (4.1)	-1.81 (2.9)	<i>0.086</i>	-0.54 (4.1)	-1.69 (4.1)	0.374	-0.57 (4.7)	-3.4 (4.4)	0.001
PWMVC	-2.07 (4.3)	-1.60 (4.1)	0.288	-2.69 (5)	-1.9 (3.5)	0.324	-4.53 (4.5)	-3.90 (4.7)	0.347
PLVVC	0.2 (5.1)	2.2 (5)	0.324	1.8 (3.7)	1.7 (3.9)	0.970	2.6 (4.5)	4.2 (6.2)	0.165
PCVC	-0.87 (3.8)	-1.86 (2.7)	0.183	-0.49 (4)	-1.65 (3.2)	0.254	-0.35 (4)	-3.34 (3.9)	0.01
PTVC	-1.14 (2.3)	-3.1 (2.7)	0.225	-0.61 (3.2)	-2.26 (4.5)	<i>0.058</i>	-1.43 (3.5)	-3.69 (5.8)	0.046
PDGMVC	-0.6 (3.9)	-1.8 (3.4)	0.385	-0.68 (4.5)	-1.5 (3.4)	0.037	-1.34 (4.3)	-4.1 (5.6)	0.008

TFM-teriflunomide; DMF-dimethyl fumarate; PBVC-percentage brain volume change; PGMVC-percentage gray matter volume change; PWMVC-percentage white matter volume change; PLVVC-percentage lateral ventricle volume change, PCVC-percentage cortical volume change; PTVC-percentage thalamus volume change; PDGMVC-percentage deep GM volume change. *p*-values derived from ANCOVA, corrected for age and sex. *p*-values shown in bold and italics are ≤ 0.05 and ≤ 0.1 , respectively.